Skip to main content

Table 1 Clinico-pathological characteristics of patients in cohort 1 and 2 split by CCND1 amplification status

From: The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours

Variable

Cohort 1 (n = 1965)

P

Cohort 2 (n = 340)

P

Non-Amp

Amp

Non-Amp

Amp

n (%)

n (%)

n (%)

n (%)

1539 (78)

426 (22)

221 (65)

119 (35)

ER

 Positive

1129 (73)

377 (88)

< 0.001

158 (71)

93 (78)

0.182

 Negative

410 (27)

49 (12)

 

63 (29)

26 (22)

 

PR

 Positive

794 (52)

231 (54)

0.364

140 (63)

71 (60)

0.504

 Negative

745 (48)

195 (46)

 

81 (37)

48 (40)

 

HER2

 Positive

190 (12)

57 (13)

0.626

40 (18)

30 (25)

0.122

 Negative

1349 (88)

369 (87)

 

181 (82)

89 (75)

 

Elston–Ellis grade

 I

148 (10)

22 (5)

0.200*

22 (10)

9 (8)

0.400*

 II

625 (43)

142 (34)

 

102 (47)

47 (40)

 

 III

690 (47)

252 (61)

 

93 (43)

62 (52)

 

 Missing cases = 86

   

Missing cases = 5

  

LN status

 Positive

748 (49)

188 (44)

0.114

116 (52)

81 (68)

0.005

 Negative

791 (51)

238 (56)

 

105 (48)

38 (32)

 

Tumour size

 < 20 mm

497 (33)

120 (28)

0.108

101 (47)

51 (43)

0.492

 ≥ 20 mm

1026 (67)

303 (72)

 

115 (53)

68 (57)

 

 Missing cases = 19

   

Missing cases = 5

  

Age

 ≤ 45

208 (14)

41 (10)

0.006

11 (12)

7 (10)

0.825

 45–55

312 (20)

69 (16)

 

78 (83)

53 (82)

 

 ≥ 55

1019 (66)

316 (74)

 

5 (5)

5 (8)

 
    

Missing cases = 181

  

IHC subgroups

 ER+/LN−/HER2−

581 (38)

190 (45)

< 0.001

64 (29)

26 (23)

0.142

 ER+/LN+/HER2−

482 (31)

145 (34)

 

75 (34)

47 (39)

 

 HER2+

190 (12)

57 (13)

 

40 (18)

30 (25)

 

 TN (ER−/PR−/HER2−)

286 (19)

34 (8)

 

42 (19)

16 (13)

 

PAM50

 Luminal A

602 (39)

116 (27)

< 0.001

77 (35)

38 (32)

0.051

 Luminal B

291 (19)

197 (46)

 

36 (16)

32 (27)

 

 HER2-enriched

184 (12)

54 (14)

 

30 (14)

20 (17)

 

 Basal-like

289 (19)

31 (7)

 

55 (25)

24 (20)

 

 Normal-like

168 (11)

27 (6)

 

23 (10)

5 (4)

 

 Missing cases = 6

      

Treatments

 Endocrine therapy

773 (50)

249 (58)

< 0.001

59 (27)

33 (27)

0.950

 Chemotherapy

196 (13)

25 (6)

 

60 (27)

30 (25)

 

 Both

148 (10)

41 (10)

 

99 (45)

55 (47)

 

 None

422 (27)

111 (26)

 

3 (1)

1 (1)

 
  1. Correlations were calculated using X2 test unless otherwise specified
  2. ER oestrogen receptor alpha, PR progesterone receptor, HER2 human epidermal growth factor 2 receptor, TN triple negative (ER−/PR−/HER2−), LN lymph node status, Amp/non-Amp CCND1 amplified/non-amplified, Both patients sequentially received chemotherapy and endocrine therapy
  3. * = Wilcoxon/Mann–Whitney
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us